NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Breakpoint Therapeutics

Breakpoint Therapeutics

Private
HamburgHealthcare & Life Scienceshttps://breakpointtx.com/

Last Round

Series A

Extension

Oct 18, 2021

Total Funding Raised

$33.6M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Breakpoint Therapeutics is a biotechnology company that discovers and develops anti-cancer drugs targeting DNA damage response mechanisms in cancer cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

DNA repair inhibitorssynthetic lethalityoncology drug discoverysmall-molecule therapeuticsDDR inhibitorsDNA damage responsecancer drug developmentpreclinical biotechtargeted cancer therapydrug out-licensingprecision oncologybiotech spin-off

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Breakpoint Therapeutics Comparables

Compare Breakpoint Therapeutics with similar companies based on industry and business-model similarity.

Breakpoint Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FoRx Therapeutics
86%
Artios Pharma
84%
Tessellate BIO
81%

Breakpoint Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionOct 18, 2021
Series AJul 8, 2019

Breakpoint Therapeutics Investors

Notable investors and investment history

Breakpoint Therapeutics investors
InvestorRounds
Taiho VenturesSeries A
BVF Partners L.P.Series A Extension
MedicxiSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors grew 315% MoM, from 445 to 1.8K.

  • Jan 21, 2026

    Oral presentation at the DDR Inhibitors Summit.

Breakpoint Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Breakpoint Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Breakpoint Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHamburg
Employee Range3
Year Founded2019
Last FundingOct 18, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.